Chemo Brain - Fact or Fiction?

Mom eats breakfast and moments later doesn’t know whether she’s eaten or not. You might assume such memory loss is to be expected at age 89, but just 2 months ago, when she was also 89, her memory was better than mine. What caused such a rapid decline? She is undergoing chemotherapy treatments for Lymphoma. Could she be suffering from “chemo brain”? When I asked Mom’s doctor about her cognitive changes, the issue was dismissed with a knowing look of “what do you expect at age 89?”. Am I surprised? Unfortunately not.

Not remembering a just-consumed meal is frightening enough, but more concerning is Mom’s inability to remember to take medications, to sort out her medications, or keep track of which medications have been prescribed for her. Seriously dangerous side effects, and yet they are not at all addressed by her doctors.

Cognitive dysfunction stemming from chemotherapy treatments is an issue that is gaining investigative attention, says Christina Meyers, MD, PhD, and Director of the Neuro-Psychology at M.D. Anderson. Meyers estimates that 60% of patients that she assesses show some measure of cognitive decline, mostly lapses in short-term memory. With numbers that high, I have to wonder why “chemo brain” is not mentioned or addressed during the initial patient consult. This is the kind of advance information patients need and want, certainly as important as the likely fact that their hair may thin during the course of treatment. It’s also the kind of information we caregivers need so that we understand exactly where we are needed. I would hate to find out that my Mom can’t keep track of her medications through a life-threatening error on her part.

Take it from me, chemo brain is real. Do not be afraid to consider the possibility that you may experience temporary mental decline as a result of your treatment and to ask for such information in advance. Once you’re in the fog, rest assured that you are not losing your mind, but experiencing a side-effect of chemotherapy. It isn’t a visible side-effect like hair loss or skin changes, but it is just as real. Be sure to tell your health care team. Knowledge is power - proactive and vocal patients can help push research in this area. We clearly need to know more about chemo brain and your important input may help researchers find ways to treat chemo brain or better yet, prevent it.

Susan M. Beausang

www.4women.com

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap